Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)dry eye syndrome, eye disorder, graft versus host disease, immune system disorder, lacrimal apparatus disorderRecruitingPhase 22026-01-20NCT07118254

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Lubris Bio Pty Ltd2

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
OTABrisbaneAustralia2
Royal Melbourne HospitalMelbourneAustralia6
Sydney Eye HospitalSydneyAustralia3